Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy

Table 2 Summary of tacrolimus genotype directed randomized controlled trials[34,35]

Limitations	Strengths
TAC initiated on day 7 (French); Single SNP studied (CYP3A5*3); Limited genotypic diversity with few CYP3A5*1/1 carriers (French); Used same dose for CYP3A5*1/1 and *1/*3 carriers (French); Genotype-based dosing did not account for clinical factors; Low risk populations and underpowered for AR; Dosing regimens designed to achieve target of 10-15 ng/mL	Established the safety of genotype directed dosing (both trials); Genotype dosing reduced time to therapeutic (French); Genotype dosing had greater proportion of troughs in range at day 3 and 10 (French); Fewer dose adjustments (French)

TAC: Tacrolimus; SNP: Single-nucleotide polymorphism.